ClinicalTrials.gg
RecruitingNCT06850038Updated Oct 23, 2026

A Study Observing the Long-term, Effectiveness and Safety of Odevixibat (Bylvay) in Patients With Alagille Syndrome (ALGS) Who Are Receiving Ongoing Treatment

An observational study in Alagille Syndrome, sponsored by Ipsen. Recruiting at 10 sites in United States. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Ipsen · Observational

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
30
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Alagille Syndrome with a site in United States — 5 open to participants now, 6 under way, 1 of them phase 3. Alagille Syndrome · United States.

Started
2025
the only one that year
Observational
9 of 17
4 open now
Registered
16th of 17
by date
Lead sponsor
1 of 17
Ipsen

Among the 17 studies in Alagille Syndrome with a site in United States, this one is the only one that started in 2025, is one of 9 observational ones, and was the 16th registered.

Alagille Syndrome

31 studies on the registry are indexed under Alagille Syndrome; 11 are open to participants now.

Browse Alagille Syndrome studies →

Open to participants now

5 of the 17 studies in Alagille Syndrome with a site in United States are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 10 Alagille Syndrome studies recruiting now, 7 (70%) set no upper age limit and 3 (30%) stop at 75 or younger; 9 take children under 18; none take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Alagille Syndrome with a site in United States, or all of them as a file.
02

Study summary

This study will collect information from patients with Alagille syndrome (ALGS) as they use odevixibat (Bylvay) in their daily lives.

Odevixibat is a medicine that helps patients with ALGS, a rare disease that harms their liver and causes itching.

The main aim of this study is to observe the long-term, everyday effectiveness and safety of the drug odevixibat in patients with ALGS who are receiving ongoing treatment.

03

Conditions studied

  • Alagille Syndrome

Browse trials for

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients diagnosed with ALGS who start treatment with odevixibat (Bylvay) will be enrolled into the registry. Patients who started odevixibat treatment before the implementation of the registry study may also be enrolled.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with ALGS.
  • On (or starting) active odevixibat treatment.
  • Signed and assent, as appropriate. Consent/assent from the participant or legal representative should be obtained, as appropriate, before any study data collection is conducted. Participants who turn 18 years of age (or legal age per country) while participating in the study will be required to provide consent for themselves.

Exclusion criteria

Exclusion Criteria:

  • Currently participating in a clinical trial with odevixibat.
  • Currently participating in any interventional clinical trial for ALGS.
  • Have any to odevixibat as per the locally approved label.
  • Had liver transplant before enrolment
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
30 participants (estimated)
Target follow-up
2 Years
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Percentage of participants with Alagille syndrome (ALGS) who are treated with odevixibat and undergo biliary diversion surgery or liver transplantation.

    Time frame: From first dose to end of study (approximately 5 years data collection)

  2. Surgical biliary diversion-free survival

    Defined as time from the start of odevixibat treatment to the first occurrence of surgical biliary diversion or death.

    Time frame: From first dose to end of study (approximately 5 years data collection)

  3. Liver transplant-free survival

    Defined as time from the start of odevixibat treatment to the first occurrence of liver transplant or death.

    Time frame: From first dose to end of study (approximately 5 years data collection)

  4. Overall survival

    Defined as time from the start of odevixibat treatment to death.

    Time frame: From first dose to end of study (approximately 5 years data collection)

Secondary outcomes

  1. Change from Baseline in Weight

    This endpoint will measure the change in participants' weight from baseline, reported as standard-deviation scores (z-scores) to account for age and sex-specific growth variations.

    Time frame: From first dose to end of study (approximately 5 years data collection)

  2. Change from Baseline in Height

    This endpoint will measure the change in participants' height from baseline, reported as standard-deviation scores (z-scores) to account for age and sex-specific growth variations.

    Time frame: From first dose to end of study (approximately 5 years data collection)

  3. Percentage of participants with Adverse Events (AEs) associated with fat-soluble vitamin (FSV) deficiencies and their possible sequelae.

    An Adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: From signing of the Informed Consent Form (ICF) to 180 days after the last dose intake of odevixibat

  4. Percentage of participants with suspected hepatotoxic Adverse events (AEs) requiring interruption of odevixibat

    An Adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: From signing of the ICF to 180 days after the last dose intake of odevixibat

  5. Percentage of participants with bleeding AEs

    An Adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: From signing of the ICF to 180 days after the last dose intake of odevixibat

  6. Percentage of participants with AEs

    An Adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: From signing of the ICF to 180 days after the last dose intake of odevixibat

07

Study locations

9 of 10 sites recruiting
  • Children's Hospital Los Angeles
    Los Angeles, California 90027, United States
    Recruiting
  • UCSF Benioff Children's Hospital
    San Francisco, California 94158, United States
    Recruiting
  • The Children's Mercy Hospital
    Kansas City, Missouri 64108, United States
    Recruiting
  • SSM Health Cardinal Glennon Children's Hospital
    St Louis, Missouri 63104, United States
    Recruiting
  • NYU Langone - NYU Grossman School of Medicine
    New York, New York 10016, United States
    Recruiting
  • Columbia University Medical Center - Morgan Stanley Children's Hospital of NewYork - Presbyterian (MS-CHONY)
    New York, New York 10032, United States
    Recruiting
  • Le Bonheur Children's Hospital
    Memphis, Tennessee 38105, United States
    Recruiting
  • Children's Medical Center Of Dallas
    Dallas, Texas 75246, United States
    Recruiting
  • Proactive El Paso,LLC
    El Paso, Texas 79902, United States
    Recruiting
  • Primary Children's Hospital (PCH) - Intermountain Healthcare/University of Utah
    Salt Lake City, Utah 84113, United States
    Not yet recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.

Time frame: Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and/or EU.

Access criteria: Further details on Ipsen's sharing criteria and process for sharing are available here (https://www.ipsen.com/science/clinical-trials/clinical-data-transparency/).

Data sharing details ↗ · www.ipsen.com

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2025 (actual). Primary completion is estimated for Nov 2030, 67 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2025
First posted
Feb 27, 2025
StartActual
Apr 22, 2025
Primary completionEst.
Nov 30, 2030
CompletionEst.
Nov 30, 2030
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
2 updates, last Oct 23, 2026
Show all 2 updates
  1. Oct 23, 2026
    Minor edits only
    + 1 other change: verification date
  2. Oct 1, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06850038
Lead sponsor
Ipsen
Responsible party
Sponsor
First posted
Feb 27, 2025
Start date
Apr 22, 2025
Primary completion
Nov 30, 2030 (estimated)
Completion
Nov 30, 2030 (estimated)
Last update
Oct 23, 2026

Study contacts

Ipsen Recruitment Enquiries
Contact
clinical.trials@ipsen.com
See email
Ipsen Medical, Director
study director · Ipsen

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion